The transforming growth factor (TGF)-β has been identified as a master regulator of liver fibrogenesis. Thus, targeting TGF-β1 pathway might modulate chronic liver disease (CLD) development and/or progression in murine model. Galunisertib (Ly2157299), already in clinical studies phase II, is an oral small molecule targeting TGF-β type I receptor (ALK-5).
SEEK ID: https://seek.lisym.org/presentations/13?version=1
Filename: LiSym_Dresden_Julia Werle_2.pdf
Format: PDF document
Size: 8.06 MB
Creator
Additional credit
Julia Werle
Submitter
Views: 2720 Downloads: 5
Created: 18th May 2017 at 13:00
Last updated: 4th Jan 2018 at 16:02
This item has not yet been tagged.
None
Version History
Version 1 (earliest) Created 18th May 2017 at 13:00 by Seddik Hammad
No revision comments